Overview of Port Delivery System With Ranibizumab
Panelists discuss how the port delivery system (PDS) is a permanent, refillable ocular implant that continuously releases ranibizumab into the vitreous, with the Archway trial demonstrating noninferior vision outcomes compared with monthly ranibizumab injections while reducing treatment burden through 6-month refill intervals.
Video content above is prompted by the following:
- Can you provide an overview of the PDS with ranibizumab approved for treating neovascular age-related macular degeneration?
- How does the device function?
- Could you discuss the key outcomes from the Archway trial for PDS?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Recent Videos
Related Content
